A Study of LY2584702 in Participants With Advanced Cancer

NCT01394003 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped The pharmacokinetic properties of the molecule do not allow for further dose escalation or development.

Conditions

Advanced Cancer

Interventions

DRUG: LY2584702

Sponsor

Eli Lilly and Company